MedTrace Logo

Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.

NCT02588716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2017-12-27

No results posted yet for this study

Summary

To evaluate the effects of Terlipressin infusion on blood loss \& transfusion requirements in cirrhotic patients undergoing major liver resections.

Conditions

  • Hepatectomy, Surgical Blood Loss, Terlipressin

Interventions

DRUG

Terlipressin

Terlipressin will be given as an intravenous injection of 2μg/kg/h to be continued throughout the surgery and weaned off over four hours postoperatively.

DRUG

normal saline

Same volumes of normal saline infusion, throughout the operation then gradually withdrawn over 4 hours.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-03-31
Completion
2016-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588716 on ClinicalTrials.gov